- Home
- ONEG vs UNCY Comparison
ONEG vs UNCY Comparison
Compare ONEG & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONEG | UNCY |
|---|---|---|
| Founded | 2021 | 2016 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.2M | 141.8M |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ONEG | UNCY |
|---|---|---|
| Price | $4.65 | $6.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $44.50 |
| AVG Volume (30 Days) | 204.5K | ★ 704.4K |
| Earning Date | 01-14-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $52,231,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.00 | $3.71 |
| 52 Week High | $13.50 | $11.00 |
Technical Indicators
Market Signals| Indicator | ONEG | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 64.64 | 51.23 |
| Support Level | $4.06 | $6.12 |
| Resistance Level | $5.29 | $6.94 |
| Average True Range (ATR) | 0.79 | 0.52 |
| MACD | 0.13 | -0.06 |
| Stochastic Oscillator | 67.75 | 45.21 |
Price Performance
Historical ComparisonAbout ONEG OneConstruction Group Limited Ordinary Shares
OneConstruction Group Ltd is a structural steelwork contractor in Hong Kong. The company is engaged in the procurement and installation of structural steel for construction projects in Hong Kong. Its construction project includes performing site preparatory and preliminary works, developing detailed work schedules and work allocation plans, implementing construction site works, and conducting site safety supervision and quality control.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.